Online Survey: "Cancer therapy and side effects in BRCA patients"
Dr. Roohi Ismail-Khan is a breast oncologist and researcher at Moffitt Cancer Center and is interested in the side effects of cancer therapy in patients with BRCA mutations. She has developed an online survey to help determine the side effect profile of BRCA carriers to cancer therapy. To be eligible for the study:
- You should be a genetic carrier of either a BRCA 1 or 2 mutation.
- You should have received treatment for cancer.
If you are interested in participating in Dr. Ismail-Khan’s survey, please contact the ICARE study team by completing our contact form or calling us at 813-745-6446 (toll free 1-800-456-3434 ext. 6446).
PARP trial in patients with BRCA1 or BRCA2 and evidence of metastatic breast cancer.
Objective: Evaluate efficacy of Veliparib in combination with other agents and compared to the combination of Platinum-based agents and taxanes.
Eligibility: Men or women with metastatic breast cancer and a documented deleterious BRCA1 or BRCA2 germline mutation.
Study Design: Randomized Phase II study to evaluate the efficacy and tolerability of veliparib in combination with TMZ vs veliparib in combination with carboplatin and paclitaxel vs placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 deleterious mutation and metastatic breast cancer who have received no more than one prior line of DNA damaging cytotoxic therapy for metastatic disease.
Funding: Abbott Laboratories
If you are interested in enrolling in this study, please complete our contact form
or call the ICARE study team at 813-754-6446 (toll free 1-800-456-3434 ext. 6446).